NBIX vs UNIT · P/E 45, rev $2.36B vs P/E 2.7, rev $722.6M
Neurocrine Biosciences Inc (NBIX) versus Uniti Group Inc (UNIT) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Uniti Group Inc (UNIT) is a reit - specialty company listed on NASDAQ.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported UNIT revenue for 2025-09-30 was $722.6M. Net income was $1.61B. Revenue was up 147.3% from 2024-09-30 to 2025-09-30. UNIT currently screens at market cap $2.96B and trailing P/E 2.7.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. UNIT currently screens at market cap $2.96B and trailing P/E 2.7.
Not investment advice. Open the NBIX and UNIT stock pages for the full models.
Not investment advice.